Apogee Therapeutics (NASDAQ:APGE – Get Free Report) and Tyra Biosciences (NASDAQ:TYRA – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations and dividends.
Risk and Volatility
Apogee Therapeutics has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, Tyra Biosciences has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500.
Valuation and Earnings
This table compares Apogee Therapeutics and Tyra Biosciences”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Apogee Therapeutics | N/A | N/A | -$255.84 million | ($4.34) | -31.03 |
| Tyra Biosciences | N/A | N/A | -$119.95 million | ($2.40) | -10.49 |
Apogee Therapeutics is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings for Apogee Therapeutics and Tyra Biosciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Apogee Therapeutics | 1 | 15 | 4 | 1 | 2.24 |
| Tyra Biosciences | 1 | 1 | 12 | 1 | 2.87 |
Apogee Therapeutics currently has a consensus price target of $121.25, indicating a potential downside of 9.97%. Tyra Biosciences has a consensus price target of $46.90, indicating a potential upside of 86.26%. Given Tyra Biosciences’ stronger consensus rating and higher possible upside, analysts plainly believe Tyra Biosciences is more favorable than Apogee Therapeutics.
Insider and Institutional Ownership
79.0% of Apogee Therapeutics shares are held by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are held by institutional investors. 24.3% of Apogee Therapeutics shares are held by insiders. Comparatively, 12.5% of Tyra Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Apogee Therapeutics and Tyra Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Apogee Therapeutics | N/A | -32.16% | -30.91% |
| Tyra Biosciences | N/A | -46.39% | -43.07% |
Summary
Tyra Biosciences beats Apogee Therapeutics on 8 of the 11 factors compared between the two stocks.
About Apogee Therapeutics
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
About Tyra Biosciences
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Receive News & Ratings for Apogee Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apogee Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
